Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 79 of 95, showing 5 Applications out of 471 total, starting on record 391, ending on 395

# Protocol No Study Title Investigator(s) & Site(s)

391.

ECCT/14/09/04  
    Assessment of Safety and Efficacy of Brozedex Syrup in the Treatment of Productive Cough. Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel Group and Multi-Site Study Conducted In Nairobi in three sites    
Principal Investigator(s)
1. Hudson Aubrey Lodenyo
Site(s) in Kenya
1. Rhodes Clinic/Ngaira Health Centre (Nairobi City county)
2. Mbagathi District Hospital (Nairobi City county)
3. Mama Lucy Hospital (Nairobi City county)
 
View

392.

ECCT/14/09/03   Breast Feeding Study
    An open-label, short-duration, repeat-dose study of breast milk excretion and infant absorption of daily oral Tenofovir Disoproxil Fumarate/Emtricitabine when used by HIV-1 uninfected lactating women    
Principal Investigator(s)
1. Jared Murray Baeten
2. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Prevention, Thika Site
 
View

393.

ECCT/14/09/02   LIVING STUDY-PHASE III B.
    Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study)   
Principal Investigator(s)
1. Elizabeth Maleche Obimbo
2. Elizabeth Bukusi
3. Winstone Nyandiko
4. Bienvenu Baruani Ngoy
5. Joseph Kariuki Mbuthia
6. Allan Godfrey Otieno
7. Lucy Koech
8. Neema Mturi
9. Beatrice Mutai
Site(s) in Kenya
1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county)
2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county)
3. MSF Belgium Kibera Clinic (Nairobi City county)
4. Gertrude\'s Children\'s Hospital (Nairobi City county)
5. Mbagathi District Hospital (Nairobi City county)
 
View

394.

ECCT/14/09/01   Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa
    An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa.   Study number: MALARIA-076 (200599)   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project
 
View

395.

ECCT/14/08/05   Brief Bactericidal Activity of Anti TB drugs
    Brief Bactericidal Activity of Anti-Tuberculosis Drugs   
Principal Investigator(s)
1. Videlis Nzioka Nduba
Site(s) in Kenya
KEMRI-CGHR
 
View